Evidence map›Paper›PMID 42014706›Full record

ArticleScientific reports2026

Streamlined spectroscopic assay for besifloxacin: A one-pot approach evaluating drugs in eye drops and aqueous humor samples based on fluorescent isoindole generation. Comprehensive evaluation of whiteness, and blueness.

Ahmed A Abu-Hassan

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ahmed A Abu-HassanDepartment of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut Branch, Al-Azhar University, Assiut, 71524, Egypt. ahmedabuhassan@azhar.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Besifloxacin (BSX) belongs to fluroquinolone-category antibiotic and marketed as ophthalmic suspension in the form of eye drops. BSX exert bactericidal by inhibiting DNA gyrase and topoisomerase IV which lead to retrogradation of cell division. The approach relies on the modification of BSX in an alkaline environment by tagging with o-phthalaldehyde. The fluorescent core was monitored using fluorimetric techniques at 434.6 nm after setting excitation at 337.9 nm. A proportional relationship was detected in the concentration range of 40–1100 ng mL− 1 for BSX, with values of detection and quantification limits equal to 12.8 and 38.7 ng mL− 1, respectively. The technique underwent validation and assessment following the standards outlined by the ICH. Furthermore, each experimental variable was meticulously examined and fine-tuned. The findings exhibit notable conformity to the prescribed reference procedure without any apparent inconsistencies between the two approaches. The designed probe shows good performance in the assay of BSX in eye drops and spiked aqueous humor. Finally, the whiteness and blueness of the methodology were assessed using corresponding metrics.

Indexed as

Aqueous HumorAzepinesFluoroquinolonesOphthalmic SolutionsFluorescent DyesHumansSpectrometry, FluorescenceAzepinesbesifloxacinFluorescent DyesFluoroquinolonesOphthalmic SolutionsBesifloxacinDeterminationEye drops, aqueous humorSpectrofluorimetric

Identifiers

PMID42014706
PMCPMC13100073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.